TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31686823

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (441 mg and 882 mg)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (441 mg)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (882 mg)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (pooled doses)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil
Number of subjects: 400
Study: 29279744

Group type: EXPERIMENTAL
Intervention: Thrombin-containing local hemostatics (TCLH)
Number of subjects: 274

Group type: COMPARATOR
Intervention: No thrombin-containing local hemostatics (Control)
Number of subjects: 274
Study: 25178517

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg/day
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Ibrutinib 840 mg/day
Number of subjects: 116
Study: 24054464

Group type: EXPERIMENTAL
Intervention: Switching to monotherapy
Number of subjects: 39
Study: 21205110

Group type: EXPERIMENTAL
Intervention: Mg-aspartate-hydrochloride (n = 27)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 52
Study: 18294180

Group type: EXPERIMENTAL
Intervention: 4 postnatal home visits (Group A)
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: 1 postnatal home visit (Group B)
Number of subjects: 876

Group type: COMPARATOR
Intervention: No home visits (Group C)
Number of subjects: 876
Study: 16648513

Group type: EXPERIMENTAL
Intervention: Locoregional therapy only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-grade tumors and/or lymphovascular invasion (LVI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other T1a,bN0M0 cases
Number of subjects: 0
Study: 12970132

Group type: EXPERIMENTAL
Intervention: High fat yoghurt with correct information (HF-C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low fat yoghurt with wrong information (LF-W)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High fat yoghurt (HF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low fat yoghurt (LF)
Number of subjects: 15
Study: 11191541

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (2 microg kg(‐1) min(‐1))
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study: 9170041

Group type: EXPERIMENTAL
Intervention: Saline flush after contrast injection
Number of subjects: 36

Group type: COMPARATOR
Intervention: No saline flush after contrast injection
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Breath-holding
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Physiologic parameters correlation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Image quality assessment
Number of subjects: 36
Study: 1331788

Group type: EXPERIMENTAL
Intervention: Vitamin D3 and calcium supplementation (1.2 g elemental calcium and 20 micrograms (800 IU) of vitamin D3 daily for 18 months)
Number of subjects: 3270

Group type: EXPERIMENTAL
Intervention: Vitamin D3 and calcium supplementation
Number of subjects: 3270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3270
Study: 31755300

Group type: EXPERIMENTAL
Intervention: Customized meditation program (weekly classes for 2 years)
Number of subjects: 323
Study: 31582283

Group type: EXPERIMENTAL
Intervention: Bevacizumab monotherapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Bevacizumab plus carboplatin
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Biomarker analysis (IHC for 19 proteins, MGMT promoter methylation)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Whole genome sequencing (WGS) of poor and exceptional survivors
Number of subjects: 54
Study: 29637421

Group type: EXPERIMENTAL
Intervention: POPS‐program (POtsdam Prevention at Schools)
Number of subjects: 1112

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 1112
Study: 26908041

Group type: EXPERIMENTAL
Intervention: 2 % carbohydrate (L-CHO) beverages
Number of subjects: 13

Group type: COMPARATOR
Intervention: 6 % carbohydrate (H-CHO) solutions with 20 g protein
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intensified training (IT)
Number of subjects: 13
Study: 24503216

Group type: EXPERIMENTAL
Intervention: Electromechanical training aid (Dynadjust™) used in year 4 of training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Aid group (control)
Number of subjects: 0
Study: 22188277

Group type: EXPERIMENTAL
Intervention: Self-adjusting File (SAF) system
Number of subjects: 40

Group type: COMPARATOR
Intervention: ProTaper rotary system
Number of subjects: 40
Study: 20703975

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate Active (BICARB A)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sodium bicarbonate Active (BICARB A) and Sodium bicarbonate Passive (BICARB P)
Number of subjects: 9
Study: 17644545

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Anti-tumour necrosis factor-alpha infliximab
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 342

Group type: COMPARATOR
Intervention: Control group (other treatment strategies)
Number of subjects: 342
Study: 16648739

Group type: EXPERIMENTAL
Intervention: OP‐1 Putty (3.5 mg OP‐1/g of collagen matrix per side)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Local autograft with HA‐TCP granules
Number of subjects: 19
Study: 14631136

Group type: EXPERIMENTAL
Intervention: ivabradine 0.25 mg/kg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10725817

Group type: EXPERIMENTAL
Intervention: Interferential current (IFC) treatment for palmar psoriasis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Interferential current (IFC) treatment
Number of subjects: 12
Study: 8840370

Group type: EXPERIMENTAL
Intervention: Intramuscular fosphenytoin (480-1500 mg loading doses, 130-1250 mg daily maintenance doses for 3-14 days)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Intravenous fosphenytoin (1082 +/- 299 mg loading doses, 411 +/- 221 mg daily maintenance doses for 3-14 days)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Intravenous phenytoin sodium (1082 +/- 299 mg loading doses, 422 +/- 197 mg daily maintenance doses for 3-14 days)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Both intravenous fosphenytoin and phenytoin sodium
Number of subjects: 206
Study: 1628722

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 6142005

Group type: EXPERIMENTAL
Intervention: Esmolol (intravenous administration)
Number of subjects: 12
Study: 31343440

Group type: EXPERIMENTAL
Intervention: RBP-7000 120 mg, administered as a monthly subcutaneous injection for 52 weeks.
Number of subjects: 500
Study: 29023683

Group type: EXPERIMENTAL
Intervention: Child group
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Parent-child group
Number of subjects: 126

Group type: COMPARATOR
Intervention: Parent group
Number of subjects: 126
Study: 27577513

Group type: EXPERIMENTAL
Intervention: Spectral CT imaging (1 ml/kg contrast agent)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional CT imaging (120 kVp, 1 ml/kg contrast agent)
Number of subjects: 60
Study: 24555418

Group type: EXPERIMENTAL
Intervention: Unloading shoes
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control shoes
Number of subjects: 164
Study: 21538098

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Usual care (UC)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Resistance training (non-ADT group)
Number of subjects: 121
Study: 21147645

Group type: EXPERIMENTAL
Intervention: He‐O₂ breathing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SF₆‐O₂ breathing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ar‐O₂ breathing
Number of subjects: 10
Study: 17230596

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg orally
Number of subjects: 11

Group type: COMPARATOR
Intervention: Fingolimod 1 mg intravenously infused over 2 h
Number of subjects: 11
Study: 14705236

Group type: COMPARATOR
Intervention: Alfacalcidol (1 micro g/day) alone (alfacalcidol group, n = 11)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 micro g/day) and intermittent cyclical etidronate (200 mg/day for 14 days, given for 4 cycles) (combined group, n = 10)
Number of subjects: 21
Study: 12203742

Group type: EXPERIMENTAL
Intervention: 6-week psychoeducational intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 89
Study: 9523407

Group type: EXPERIMENTAL
Intervention: Mortality Salience (MS)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control topic
Number of subjects: 4
Study: 7665805

Group type: EXPERIMENTAL
Intervention: Bright-light therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dim light (after bright-light therapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bright-light therapy (control group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dim light (control group)
Number of subjects: 30
Study: 2744907

Group type: EXPERIMENTAL
Intervention: Pinaverium bromide (10 subjects)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (10 subjects)
Number of subjects: 20
Study: 58258

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 30818311

Group type: EXPERIMENTAL
Intervention: Topical sialagogue spray containing malic acid 1% (SalivAktive®)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 28493922

Group type: EXPERIMENTAL
Intervention: Biodegradable system (Inion CPS)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Titanium system (KLS Martin)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Both groups (Biodegradable and Titanium)
Number of subjects: 221
Study: 25613996

Group type: EXPERIMENTAL
Intervention: Berlin Heart EXCOR(®) device
Number of subjects: 204
Study: 23334820

Group type: EXPERIMENTAL
Intervention: 12-unit, interactive, standardized programme based on the comprehensive social influence model
Number of subjects: 173
Study: 22164629

Group type: EXPERIMENTAL
Intervention: Tribendimdine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 47
Study: 19631559

Group type: COMPARATOR
Intervention: JVIR articles
Number of subjects: 215

Group type: COMPARATOR
Intervention: CVIR articles
Number of subjects: 215

Group type: COMPARATOR
Intervention: Randomized studies in JVIR
Number of subjects: 215

Group type: COMPARATOR
Intervention: Randomized studies in CVIR
Number of subjects: 215
Study: 17082278

Group type: EXPERIMENTAL
Intervention: High-viscosity glass ionomer cement (GIC)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Resin-based composite
Number of subjects: 219

Group type: COMPARATOR
Intervention: Comparison of Class II restorations
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 219
Study: 12832297

Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet
Number of subjects: 36

Group type: COMPARATOR
Intervention: High-glycemic index diet
Number of subjects: 36
Study: 11016777

Group type: EXPERIMENTAL
Intervention: iobitridol 300 (low‐osmolar, 300 mg I/ml)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: iobitridol 350 (low‐osmolar, 350 mg I/ml)
Number of subjects: 212

Group type: COMPARATOR
Intervention: ioxithalamate 350 (high‐osmolar, 350 mg I/ml)
Number of subjects: 212
Study: 8843536

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clonazepam
Number of subjects: 16
Study: 1617576

Group type: EXPERIMENTAL
Intervention: Relaxing music therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 40
Study: 6703818

Group type: EXPERIMENTAL
Intervention: Intravenous verapamil hydrochloride (0.075 mg/kg and 0.15 mg/kg given 15 minutes apart)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous verapamil hydrochloride
Number of subjects: 14
Study: 30221330

Group type: EXPERIMENTAL
Intervention: Intravenous and intra-articular TXA and RIV postoperatively (Group A)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Intravenous and intra-articular TXA and LMWH postoperatively (Group B)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Saline and RIV postoperatively (Group C)
Number of subjects: 158
Study: 31584145

Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol (ICS-LABA) as rescue medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol (ICS-LABA) on demand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol (ICS-LABA) used as needed
Number of subjects: 0

Group type: COMPARATOR
Intervention: ICS-LABA combination used as needed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic ICS treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: SABA alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mometasone (ICS) and tiotropium (antimuscarinic)
Number of subjects: 0
Study: 28598858

Group type: EXPERIMENTAL
Intervention: Real iTBS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 10
Study: 25740537

Group type: EXPERIMENTAL
Intervention: D2-receptor antagonist amisulpride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23748693

Group type: EXPERIMENTAL
Intervention: Mixed observation (both expert and novice models)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed observation and expert observation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical practice trials interspersed with observation
Number of subjects: 0
Study: 21489663

Group type: EXPERIMENTAL
Intervention: diet + PS (2 g/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: healthy diet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: healthy diet + PS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PS supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: diet
Number of subjects: 24
Study: 18577159

Group type: EXPERIMENTAL
Intervention: Basal insulin (insulin glargine) added to existing oral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin (insulin glulisine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimization of basal insulin dose with addition of prandial insulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basal-bolus insulin strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Premixed insulin strategy
Number of subjects: 0
Study: 17137975

Group type: EXPERIMENTAL
Intervention: Nonventing curette with pump settings of 5 mL/min and 10 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venting curette with pump settings of 7 to 10 mL/min and 50 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bypass hole in the curette
Number of subjects: 0
Study: 12617523

Group type: EXPERIMENTAL
Intervention: Modified wavelet de‐noising procedure
Number of subjects: 12
Study: 11406327

Group type: EXPERIMENTAL
Intervention: Compensatory visual field training for 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (23 healthy individuals)
Number of subjects: 21
Study: 9256222

Group type: EXPERIMENTAL
Intervention: Abciximab bolus plus infusion
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Abciximab bolus only
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 2099
Study: 8273616

Group type: EXPERIMENTAL
Intervention: Low-osmolality radiologic contrast media
Number of subjects: 1004

Group type: COMPARATOR
Intervention: High-osmolality radiologic contrast media
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Cardiac angiography
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Body CT
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: History of unstable angina
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: No history of unstable angina
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: History of renal insufficiency
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: No history of renal insufficiency
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Two adverse reactions
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Three or more adverse reactions
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Thromboembolic reaction
Number of subjects: 1004
Study: 3305620

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-fluoride gel
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fluoride gel
Number of subjects: 34
Study: 30962409

Group type: EXPERIMENTAL
Intervention: HL301 (600 mg/day)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 30303956

Group type: EXPERIMENTAL
Intervention: Women empowerment intervention
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: Trauma exposure
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: Childhood trauma exposure
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: Community gender attitudes
Number of subjects: 1463
Study: 28090203

Group type: EXPERIMENTAL
Intervention: Herbal extracts (experimental group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (glasses without herbal extracts)
Number of subjects: 32
Study: 23911560

Group type: EXPERIMENTAL
Intervention: Surgical staging via a minimally invasive extraperitoneal approach followed by tailored radiotherapy with chemotherapy
Number of subjects: 600

Group type: COMPARATOR
Intervention: Pelvic radiotherapy with chemotherapy (standard-of-care arm)
Number of subjects: 600
Study: 23093136

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (n=265) aiming at weight reduction, dietary modification, and increased physical activity.
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group (n=257) receiving general lifestyle information.
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (n=265)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group (n=257)
Number of subjects: 522
Study: 21481394

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg + Simvastatin 20mg (EZE+S)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo + Simvastatin 20mg (P+S)
Number of subjects: 15
Study: 18086800

Group type: EXPERIMENTAL
Intervention: Adjuvant oophorectomy and tamoxifen for 5 years
Number of subjects: 709
Study: 16513003

Group type: EXPERIMENTAL
Intervention: Levodopa (200 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Aging
Number of subjects: 64
Study: 12695318

Group type: EXPERIMENTAL
Intervention: Group psychoeducation (21 sessions)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nonstructured group meetings (21 sessions)
Number of subjects: 120
Study: 11123451

Group type: EXPERIMENTAL
Intervention: Clotrimazole troche (10 mg, five times daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Itraconazole oral solution (100 mg/10 mL, twice daily)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Clotrimazole troche
Number of subjects: 29

Group type: COMPARATOR
Intervention: Itraconazole oral solution
Number of subjects: 29
Study: 9368814

Group type: EXPERIMENTAL
Intervention: Iron fortification present
Number of subjects: 15

Group type: COMPARATOR
Intervention: Iron fortification withdrawn
Number of subjects: 15
Study: 8469556

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (0.025%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate (0.12%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Iso‐Dent (control)
Number of subjects: 30
Study: 3328853

Group type: EXPERIMENTAL
Intervention: Flupirtine (100 mg capsules and 150 mg suppositories)
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Flupirtine
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study: 29793857

Group type: EXPERIMENTAL
Intervention: Tralokinumab (300 mg) administered subcutaneously every 2 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo administered subcutaneously every 2 weeks
Number of subjects: 79
Study: 25812080

Group type: EXPERIMENTAL
Intervention: Attachment-focused integrative reminiscence (AFIR) intervention
Number of subjects: 0
Study: 24966303

Group type: EXPERIMENTAL
Intervention: Multiple sclerosis group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 23025333

Group type: EXPERIMENTAL
Intervention: Cultured graft consisting of autologous cultured melanocytes on poly (DL‐lactic acid) film
Number of subjects: 22

Group type: COMPARATOR
Intervention: Polyurethane dressing (control arm)
Number of subjects: 22
Study: 16317125

Group type: EXPERIMENTAL
Intervention: Whole flaxseed
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Crushed flaxseed
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ground flaxseed
Number of subjects: 12
Study: 12181509

Group type: EXPERIMENTAL
Intervention: Hearing aid provision
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no hearing aid provision)
Number of subjects: 133
Study: 9695717

Group type: EXPERIMENTAL
Intervention: Disulfiram (500 mg oral)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 10
Study: 7647823

Group type: EXPERIMENTAL
Intervention: Moderately energy-restricted diet (ER)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (weight-maintaining diet)
Number of subjects: 24
Study: 2757680

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine preparation (test preparation)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Marketed reference preparation (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both preparations (test and reference)
Number of subjects: 16
Study: 320940

Group type: EXPERIMENTAL
Intervention: 1% clotrimazole solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 31758926

Group type: EXPERIMENTAL
Intervention: Monthly 0.3‐mg intravitreal ranibizumab injections
Number of subjects: 24